On 12 May the Scottish Medicines Consortium (SMC) announced that raltegravir (Isentress) has been accepted for restricted use within NHS Scotland in combination with other antiretroviral medicinal products agents for the treatment of HIV-1 in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. [1]

It is restricted to patients with triple class resistant HIV-1 infection.

Raltegravir was approved in Europe on 23 January. [2]

References

1. SMC press release (12 May)
http://www.scottishmedicines.org.uk/smc/5727.html
2. See HTB January/February
http://i-base.info/htb/1773